The Fertility Show, Manchester Central, 24-25 March 2018
Page URL:

'Landmark' neural stem cell trial underway

21 March 2011
Appeared in BioNews 600

A US company has launched an experimental neural stem cell clinical trial for patients paralysed by spinal injury. StemCells Inc will extract neural stem cells from donated aborted fetuses to be injected into the spines of patients with chest-level spinal cord injury.

Dr Armin Curt, Medical Director of the Paraplegic Center at the Balgrist University Hospital, Switzerland, will lead what he believes to be a 'landmark trial' designed to administer the experimental therapy. 'For patients facing a lifetime of paralysis, the prospect that neural stem cell transplantation may one day help restore some degree of function offers new hope', Dr Curt said.

Dr Stephen Huhn, vice-president and head of the central nervous system programme at StemCells Inc told the Times last week: 'We are hoping to see incremental improvement that could well improve quality of life. It might be improvement in motor function, but it could be as simple as improved bladder or sexual function'.

Fetal neural stem cells have already differentiated, or been 'programmed', to generate into any of the central nervous system cell types. This makes them distinct from undifferentiated embryonic stem cells, which have the potential to become any cell type in the body.

Animal studies demonstrated that, when fetal neural stem cells are injected into the spines of paralysed animals, they can produce new specialised cells that help regenerate function without causing tumours or other adverse results. In particular, they were found to turn into oligodendrocytes, which regenerate nerves' protective myelin sheaths that commonly become damaged by injury.

British patients may apply to participate in the trial, but overall numbers are limited. Three groups of patients with different degrees of injury will be enrolled to take part in the trial. The first group will include patients who have no movement or feeling below the area of injury, the second will include patients who have some feeling below the injury, and the third group will include patients who experience some movement. Twelve patients in total will take part.

Dr Curt, who will monitor patient safety and therapeutic efficacy, is excited by the 'innovative design' of the trial, which 'will progress from the most severely injured to less severely injured' enabling the opportunity to observe a range of mechanisms for potential benefits.

The trial differs from another US spinal cord clinical trial begun in California last year by Geron, which applies human embryonic stem cells to patients with new spinal cord injuries. The StemCells Inc trial is believed to be the first to use fetal neural stem cells applied to older injuries, sustained three to 12 months beforehand.

Each patient group will be assessed over one year with an additional four-year observation period following completion of the trial. StemCells Inc has neural stem cell clinical trials already active for two fatal neurodegenerative childhood conditions.
New stem cell treatment offers hope for spinal cord injuries
The Times (subscription required) |  14 March 2011
StemCells Inc initiates world's first neural stem cell trial in spinal cord injury
News release - StemCells Inc |  14 March 2011
StemCells, Inc. Initiates World's First Neural Stem Cell Trial in Spinal Cord Injury
MSNBC |  14 March 2011
StemCells starts spinal cord injury trial
San Francisco Business Times |  14 March 2011
6 February 2012 - by Ruth Retassie 
US company StemCells Inc have received Food and Drug Administration (FDA) authorisation to carry out clinical trials of their treatment for one of the leading causes of blindness in over 55-year-olds...
18 October 2010 - by Dr Lux Fatimathas 
A patient paralysed through spinal cord injury has become the first person to receive human embryonic stem (ES) cell treatment in a clinical trial being conducted in the United States...
23 August 2010 - by Kyrillos Georgiadis 
Japanese researchers have overcome a major obstacle to treating severe spinal cord injuries using stem cells taken from the brain...
28 September 2009 - by Dr Marianne Kennedy 
The US Food and Drug Administration (FDA) has granted approval to NeuralStem Inc., a Maryland-based biotherapeutics company, to conduct the first human trial using neural stem cells for treatment of amyotrophic lateral sclerosis (ALS). ALS is a type of motor neuron disease often referred to as 'Lou Gehrig's' and 'Maladie de Charcot'. The late-onset condition, of unknown cause, affects approximately two in 100,000 people, including the UK physicist Stephen Hawking and US rock gui...
6 September 2009 - by Nishat Hyder 
Information has come to light regarding the US Food and Drug Adminstration (FDA)'s freeze on the clinical trails of GRNOPC1, a groundbreaking therapy for spinal cord injury derived from human embryonic stem cells (ES cells) being undertaken by biotech company Geron...
23 August 2009 - by Alison Cranage 
The US Food and Drug Administration (FDA) has delayed the start of a clinical trial that plans to use human embryonic stem cell(ES) cells to treat spinal cord injury. The trial is being run by Californian based company Geron. The FDA originally gave the go-ahead for the trial in January, but now has halted the start in order to review new data submitted by Geron....
22 September 2008 - by Alison Cranage 
Researchers have generated a specialised type of nerve cell - astrocytes - from embryonic stem (ES) cells. The astrocytes were used to treat spinal injury in rats, with impressive results, restoring their ability to move freely. The team of scientists from the University of Rochester, New York, and the...
30 March 2006 - by BioNews 
Canadian researchers have used a cocktail of stem cells, growth hormones and anti-inflammatory drugs to treat rats with spinal injuries. The team, based at the Toronto Western Research Institute, say that the treatment restored some walking ability and limb control in the animals. The research, published in the Journal of...
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.